November is Lung Cancer Awareness Month💙 At Hedera Dx, we’re advancing lung cancer care with longitudinal tumor profiling & treatment monitoring through non-invasive liquid biopsy and NGS. #LungCancerAwarenessMonth #PrecisionOncology

Movember is here🎗️ Join us in raising men’s health awareness, every mustache grown and conversation started can make a difference! #Movember

🚨 New Release! 🚨 The manuscript “Analytical Validation of a Pan-Cancer NGS Assay for In-House Liquid Biopsy Testing” is now live on medRxiv! Check it out here 👉 https://t.co/KJKhVN57z7 #LiquidBiopsy #CancerCare

One of the most promising advancements in oncology is liquid biopsy. But what makes this technology a game-changer? Learn more on our website and discover how we can partner together: https://t.co/cdlJzbuoA3 #LiquidBiopsy #Clinicogenomics #RWE #PrecisionOncology

June is Cancer Immunotherapy Awareness Month🎗️ Hedera Dx is dedicated to pioneering advancements in oncology care through our cutting-edge liquid biopsy solutions, including MSI testing which play a crucial role in guiding immunotherapy across many cancer types. #Immunotherapy

New review published in Cell highlights the transformative potential of liquid biopsy in cancer care, emphasizing its non-invasive ability to capture tumor heterogeneity and detect clinically actionable mutations, with remarkable sensitivity! https://t.co/RBosjWgOUm

Over 19 million new cases of cancer are reported each year. Yet 30-50% of all cancers remain preventable. Reduce the risks of cancer with healthier behaviours, regular screening, earlier detection and timely treatment. #WorldCancerDay https://t.co/AP6pR7EGcG

📷 Save the Date: Mark your calendar for this transformative liquid biopsy talk at Precision Medicine World Conference 2024, to be given by our CMO & Co-founder, Dr Christian Meisel. Learn more : https://t.co/SkuK0opK9o #LiquidBiopsy #PMWC24

As the year winds down, we want to express our gratitude for your ongoing support & trust. May your holidays be filled with joy, warmth, and moments of connection. Here’s to a fantastic new year filled with new opportunities and shared success! 🥂🌟 #NewBeginnings #Happy2024

Liquid biopsies, one of the most transformational innovations in oncology. By analyzing a small amount of DNA shed by the tumor in the blood, liquid biopsy enhances our understanding of cancer, its evolution over time, and its response to treatments. https://t.co/x7wLrr6OI5

Hedera Dx recognized as one of the most promising startups for biomarker & liquid biopsy in 2024! 🙌 Named in Top 20 for Biomarker development and ranked in the Top 2 for Liquid Biopsy (based on an independent data-driven analysis of > 850 startups) https://t.co/AguO47kbcP

New Product Launch Announcement – Hedera Profiling 2 ctDNA test panel, at the forefront of actionability for liquid biopsy testing, is now available for solid tumors 📷 https://t.co/ISQKaduNKV #TargetedTherapy #ImmunoOncology #PrecisionOncology #Announcement

Exciting News! Hedera Dx Launches New Liquid Biopsy Solution Discover our comprehensive solution to be run in local hospital labs, bringing liquid biopsy testing to a broader range of patients for them to get access to better therapy options https://t.co/53AH7NZ7Cm #CancerCare

Hedera Dx is super happy to attend @BioTechX_ 2023, Switzerland 🙌 Feel free to meet our team at booth S36 in the startups area to learn more about what we do or to connect with our participants via DM (@tommi_lehtonen, CEO and @ThomVett, Director BioIT & ML)!

Breast cancer affects > 2 million new women each year. With a 5-year survival rate > 90% when detected early, it remains among the most treatable forms of cancer. Early detection (routine self-examinations, screenings) are pivotal for ensuring successful treatment. #BreastCancer

Check out the latest ESMO Clinical Practice Guidelines for #PancreaticCancer with essential insights on diagnosis, staging, treatment, and supportive care. It includes helpful algorithms and scoring systems such as ESMO-MCBS & ESCAT ones. https://t.co/bcF6DGwdU4

Thyroid Cancer affects > 500 000 patients worldwide. Understanding its risks, symptoms & treatment options is crucial to keep reaching high survival rates (up to 98.5% for 5-year relative survival rate). #ThyroidCancerAwareness https://t.co/ykn8ygYZMz

Exciting Advances in mCRC Management! A review in Clinical Cancer Research explores longitudinal liquid biopsy testing in mCRC. It detects actionable targets, tracks early responses & suggests optimal rechallenge times.#ColorectalCancer #LiquidBiopsy

On World Lung Cancer Day, let’s unite to make a difference! Raise Awareness, Advocate for Change, and Educate to support those battling lung cancer worldwide. Learn more: https://t.co/oAjTqMqfql #WLCD23 #LungCancerAwareness

Exciting survey results on molecular pathology testing! 275 labs across 45 countries participated. 89% conduct tests, 64% offer plasma ctDNA diagnostic service testing. Interest in ctDNA testing is rising (56% vs. 34% in 2017) #LiquidBiopsy #CancerTesting